Stay updated with breaking news from Week Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Keep up the unhappy possibilities that impact IT resiliency -- from ransomware, to cloud outages, to natural disasters, to political upheaval -- and learn what to do about them.
This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 09.10.2023 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Reports Positi...
– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis P...
Free Newsletter to InformationWeek Today Newsletter. Subscribe and get a snapshot of the issues affecting the IT industry. You'll hear about hot happenings and businesses that are leveraging technology to drive their operations forward.